Quick Takeaways:
- Zomedica has entered a strategic collaboration with Boehringer Ingelheim Animal Health Canada to expand point-of-care testing for pituitary pars intermedia dysfunction (PPID) in horses. The program will use Zomedica’s TRUFORMA platform and begins with Canada’s fall testing season.
- Under the collaboration, Zomedica will place TRUFORMA analyzers at participating equine veterinary practices at no cost, while eligible Boehringer Ingelheim customers will receive complimentary testing and diagnostic cartridges. The program will use TRUFORMA’s equine endogenous ACTH (eACTH) and equine insulin assays, with access to additional assays including Cortisol and Progesterone.
- PPID, formerly known as equine Cushing’s disease, affects approximately 20–25% of horses over 15 years of age. By bringing endocrine testing directly into veterinary practices, the companies aim to enable faster diagnosis and treatment monitoring, particularly across Canada’s geographically dispersed equine practices. The collaboration is also expected to expand Zomedica’s installed base and drive recurring diagnostic revenue.
Why It Matters?
By putting TRUFORMA analyzers in equine clinics at no cost and offering free PPID testing cartridges to eligible Boehringer Ingelheim customers, the program makes it much easier and faster for vets to diagnose and monitor Cushing’s disease in horses without sending samples to a lab. This should increase testing rates (especially in Canada’s fall season when PPID screening peaks), improve early detection and treatment for older horses, and help Zomedica grow its installed base and recurring revenue as vets add more TRUFORMA assays like insulin, cortisol and progesterone.
Source: Access Newswire
